Lantern Pharma Inc.

LTRN

$1.87

-3.11%

2026-09-03 16:00:01 EDT-$0.06

Healthcare

Biotechnology

NASDAQ

Negociación activa

Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, ...

Evolución del precio de LTRN

$1.87

-3.11%-$0.06

Máximo—

Mínimo—

Máx. 52s-60.2%

Vol. rel.—

Intervalo

Rango4.5h

Volumen—SMA5SMA10

—

Lantern Pharma Inc. is a clinical-stage biotechnology firm headquartered in Dallas, Texas, dedicated to transforming oncology drug development through the strategic integration of artificial intelligence (AI), machine learning, and comprehensive genomic data analysis. Founded in 2013, the company operates with a lean team of 16 employees, focusing on precision medicine ...Lantern Pharma Inc. is a clinical-stage biotechnology firm headquartered in Dallas, Texas, dedicated to transforming oncology drug development through the strategic integration of artificial intelligence (AI), machine learning, and comprehensive genomic data analysis. Founded in 2013, the company operates with a lean team of 16 employees, focusing on precision medicine and biomarker-driven therapies to reduce the time and cost associated with traditional drug development. Their core proprietary platform, RADR (Response Algorithm for Drug Repositioning and Response), synergizes molecular data, big data analytics, and machine learning to identify patient populations most likely to respond to specific drug candidates, thereby enhancing clinical trial success rates. The company's pipeline includes three lead drug candidates and an antibody-drug conjugate (ADC) program across 12 cancer indications. LP-100, their most advanced candidate, is currently in Phase II clinical trials for metastatic castration-resistant prostate cancer. LP-300 is being developed as a combination therapy for non-small cell lung cancer adenocarcinoma in non-smokers or never-smokers, while LP-184 is a preclinical alkylating agent designed to target DNA repair pathways in cancer cells with specific biomarkers or mutations. Financially, as a clinical-stage company with no revenue, Lantern Pharma relies on funding from public markets and potentially partnerships. With a market capitalization of approximately $35.47 million as of the latest data, the company faces typical clinical-stage risks, including high R&D expenditures and significant cash burn, reflected in negative operating cash flow and profitability metrics. Key leadership includes CEO and President Panna Sharma, who spearheads the company's vision of merging AI with precision oncology, and CFO David R. Margrave, overseeing financial strategy. The company's mission, encapsulated in its tagline 'AI for good,' aims to advance machine learning-driven drug discovery to improve patient care and ultimately crush cancer. With a committed focus on innovation and strategic drug repurposing, Lantern Pharma represents a forward-thinking approach in the biotechnology sector, targeting previously hard-to-treat cancers through advanced computational biology.ExpandirContraer

Fundación

2013

Empleados

CEO

Panna Sharma

Nombre completo

Lantern Pharma Inc.

Sector

Healthcare

Industria

Biotechnology

ROE

-456.35%

Capitalización

$0.02B

Ratio corriente

1.96

WACC

6.79%

ROIC

-444.23%

Información de contacto

https://www.lanternpharma.com

972 277 1136

1920 McKinney Avenue, Dallas, TX 75201

Métricas clave de LTRN

Instantánea

Último / TTM · 6 periodos

Capitalización

$23.86M

ROCE

-361.4%

EV / EBITDA

-0.92x

-86.2% YoY

Rendimiento FCF

-59.0%

-11.5% YoY

Ciclo de conversión de efectivo

0.0d

Ratio corriente

1.96

Resumen rápido

TTM —

Sin señales de riesgo importantes en las métricas seleccionadas.

Aspectos financieros de LTRN

Tendencia de rentabilidad

Último / TTM · 6 periodos

Margen bruto

0.0%

Margen neto

0.0%

PER

-1.15x

n/d

Deuda / capital

-0.01

n/d

Ratio corriente

1.96

Rendimiento del dividendo

0.0%

Comprensión

TTM —

La cobertura de intereses es débil

Calendario de LTRN

Próximamente

30 sept 2026En 26 días
Q3 FY2026 · Resultados estimados
BPA est. $-0.35 · Ingresos $0.00 · 1 analistas
30 dic 2026
Q4 FY2026 · Resultados estimados
BPA est. $-0.41 · Ingresos $0.00 · 1 analistas
31 dic 2026
FY2026 · Resultados anuales estimados
BPA est. $-1.63 · Ingresos $1.95M · 1 analistas
31 dic 2027
FY2027 · Resultados anuales estimados
BPA est. $-2.02 · Ingresos $14.60M · 1 analistas

Historial reciente

14 ago 2026
Q2 FY2026 · Resultados publicados
BPA $-0.57 · Ingresos $0.00
Ver documento
15 may 2026
Q1 FY2026 · Resultados publicados
BPA $-0.30 · Ingresos $0.00
Ver documento
30 mar 2026
FY2025 · Resultados anuales
BPA $-1.57 · Ingresos $0.00
Ver documento
12 nov 2025
Q3 FY2025 · Resultados publicados
BPA $-0.39 · Ingresos $0.00
Ver documento
13 ago 2025
Q2 FY2025 · Resultados publicados
BPA $-0.40 · Ingresos $0.00
Ver documento
15 may 2025
Q1 FY2025 · Resultados publicados
BPA $-0.42 · Ingresos $0.00
Ver documento

Estados financieros de LTRN

Tendencia de 5 años (ingresos, beneficios, FCF)

Métrica	Último	InteranualYoY significa Year-over-Year (interanual). Compara el último valor anual con el valor anual anterior para mostrar la fortaleza de la tendencia a largo plazo.	TrimestralQoQ significa Quarter-over-Quarter (intertrimestral). Compara el último trimestre con el trimestre inmediatamente anterior para mostrar cambios de impulso a corto plazo.
IngresosEl dinero total que entró por la puerta principal al vender cosas, antes de pagar una sola factura. Piensa en esto como el gran total de cada compra con tarjeta de los clientes. (YoY compara el rendimiento de este año con el del año pasado, mientras que QoQ compara los tres meses actuales con los tres anteriores).	$0	—	—
Beneficio netoEl resultado final absoluto. Si la empresa pagara a cada proveedor, empleado, banquero y recaudador de impuestos, este es el dinero real que queda en su bolsillo al final del día.	$-17.1M	+17.6%	-112.4%
Margen brutoEl margen básico. Si venden unas zapatillas de 100 dólares, este porcentaje indica cuánto de ese precio es ganancia justo después de pagar el caucho y los cordones, pero antes de pagar el alquiler de la tienda o los anuncios de televisión.	—	—	—
Margen operativoLa puntuación de eficiencia del 'trabajo diario'. De cada dólar que gasta un cliente, esto muestra cuántos centavos mantiene la empresa después de fabricar el producto Y pagar todos los gastos generales corporativos (como salarios, marketing y mantener las luces encendidas).	—	—	—
Margen netoEl porcentaje final que se lleva a casa. Cuando se eliminan todos los costos concebibles, impuestos y pagos de intereses, este es el número exacto de centavos que la empresa realmente se queda de cada dólar en ventas.	—	—	—
Flujo de caja libreEl santo grial del efectivo corporativo. Es el dinero físico gastable que queda después de que el negocio paga sus operaciones diarias Y compra las actualizaciones grandes y costosas (como nuevas fábricas o servidores) que necesita para sobrevivir. Este es el dinero 'libre' que pueden usar para pagar dividendos o recomprar acciones.	$-15.7M	+12.0%	+22.0%
Margen FCFLa tasa definitiva de conversión de efectivo. Muestra qué tan buena es la empresa para convertir ventas regulares directamente en efectivo frío, duro y gastable. Un porcentaje alto significa que el negocio es una auténtica máquina de imprimir dinero.	—	—	—
Deuda/PatrimonioEl indicador de riesgo financiero. Compara cuánto del imperio de la empresa se construyó con dinero prestado (préstamos) frente al dinero propio de los propietarios (accionistas). Un número alto significa que están muy apalancados y juegan un juego más arriesgado; un número bajo significa que juegan a lo seguro.	1202.0%	+104419.6%	-172.0%
Ratio corrienteLa verificación de supervivencia de 12 meses. Simplemente compara el efectivo que tienen ahora mismo (más cosas que pueden convertirse rápidamente en efectivo) con las facturas inmediatas que absolutamente deben pagar este año. Una puntuación superior a 1 significa que tienen suficiente en la billetera para cubrir las próximas facturas sin entrar en pánico.	2.40x	-58.8%	+4.7%
Activos totalesEl tamaño absoluto del imperio de la empresa. Agrupa absolutamente todo lo valioso que poseen, desde el efectivo en la caja registradora y el inventario en el almacén, hasta las patentes de software en la bóveda y las fábricas en el suelo.	$11.0M	-56.8%	+19.1%

Real vs estimado

A Dec 31Q Jun 30

Métrica	Anual (real vs estimado)	Sorpresa anual	Trimestral (real vs estimado)	Sorpresa trimestral
EPS Surprise	-1.57 vs -1.67	+6.0%	-0.57 vs -0.38	-50.0%
Revenue Surprise	—	—	—	—

Transacciones de insiders de LTRN

Compras (A)

Since Jan 9, 2026

Ventas (D)

Since Jan 9, 2026

Acciones mensuales compradas/vendidas con tendencia del precio de cierre (fuente diaria compartida)

Resumen de trading de insiders

Fecha	Ejecutivo	Cargo	Valor	Lado	Acciones	Precio
May 12, 2026	Schalop Lee Troy	director	Common stock purchase warrant (Right to Buy)	D	48,544	$2.27
May 12, 2026	Schalop Lee Troy	director	Common stock, $0.001 par value	A	48,544	$2.06
May 12, 2026	KEYSER D JEFFREY	director	Common stock, $0.001 par value	A	48,544	$2.06
May 12, 2026	KEYSER D JEFFREY	director	Common stock purchase warrant (Right to Buy)	D	48,544	$2.27
Jan 9, 2026	KEYSER D JEFFREY	director	Stock Option (Right to Buy)	A	28,844	$3.49

Transcripción de la llamada de resultados de LTRN

1 segmentos de transcripción

Q2 2026

Ponente desconocido

Operator: Management's presentation. A webcast replay of today's conference call will be available on our website at lanternpharma.com shortly after the call. We issued a press release before market opened today, summarizing our financial results and progress across the company for the second quarter ended 06/30/2026. A copy of this release is available through our website at lanternpharma.com, where you will also find a link to the slides management will be referencing on today's call. We would like to remind everyone that remarks about future expectations, performance, estimates, and prospects constitute forward looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 2 thousand. Lantern Pharma cautions that these forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated. A number of factors could cause actual results to differ materially from those indicated by forward looking statements, including results of clinical trials, and the impact of competition. Additional information concerning factors that could cause actual results to differ materially from those in the forward looking statements can be found in our annual report on Form 10 ks for the year ended 12/31/2025. Which is on file with the SEC and available on our website. Forward looking statements made on this conference call are as of today, August 14, 2026, and Lantern Pharma does not intend to update any of these forward looking statements to reflect events or circumstances that occur after today unless required by law. The webcast replay of the conference call and webinar will be available on Lantern's website. On today's webcast, we have Lantern Pharma's CEO, Panna Sharma and CFO. David R. Margrave. Panna will start things off with an overview of Lantern's strategy and business model, and highlight recent achievements in our operations. After which, David will discuss our financial results. This will be followed by some concluding comments from Panna. And then we will open the call for Q&A. I would now like to turn the call over to Panna Sharma. President and CEO of Lantern Pharma. Panna, please go ahead. Panna Sharma: Good morning, everyone, and thank you for joining us. To discuss our second quarter 26 results. As I have said before, AI and computationally driven approaches are now becoming central to how both large and emerging biopharma companies discover and develop drugs, but also how they allocate their resources and think about staffing their scientific teams. Today, we are at an inflection point that is actually accelerating not just for Lantern, but for how science itself will be conducted. And we are watching it happen in real trials with real patients at Lantern. The golden age of artificial intelligence in medicine is not beginning. it is actually accelerating. And this quarter, that idea has resulted in the development of a new …

Equipo directivo de LTRN

5 directivos

Nombre	Cargo	Remuneración	Género	Año de nacimiento	Estado
Panna Sharma	President, Chief Executive Officer & Director	USD 763,750	Male	1971	Active
David R. Margrave	Chief Financial Officer & Secretary	USD 540,780	Male	1961	Active
Kishor Gopaldas Bhatia	Chief Scientific Officer & Scientific Consultant	USD 222,024	—	1955	Active
Peter L. Nara	Co-Founder & Advisor	—	—	—	Active
Marc C. Chamberlain	Chief Medical Officer of Starlight Therapeutics	—	—	—	Active

Noticias recientes de LTRN

Seeking Alpha14/8/2026Neutral

Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript

Business Wire14/8/2026Neutral

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update.

GuruFocus7/8/2026Neutral

Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (âAIâ) company developing targeted and transformative cancer therapies using its proprietary

Business Wire7/8/2026Neutral

Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET

DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET.

GuruFocus3/8/2026Neutral

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and th

Evolución del número de empleados de LTRN

Actual

Cambio

-33.33%

Mínimo

Máximo

Presentaciones recientes

Fecha del informe	Empleados	Tipo de formulario	Fecha de presentación	Archivo SEC
31 dic 2025	16	10-K	30 mar 2026	Ver
31 dic 2024	24	10-K	27 mar 2025	Ver
31 dic 2023	21	10-K	18 mar 2024	Ver
31 dic 2022	22	10-K	20 mar 2023	Ver
31 dic 2021	14	10-K	10 mar 2022	Ver

Acciones relacionadasBiotechnology

Ver todas las acciones de EE. UU. →

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal

Lantern Pharma Inc.